B+
Bull case
25%
Probability
Target price
$73.50
+6.3% vs current
SYRE
Spyre TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$54.29
-21.5% vs current
B-
Bear case
15%
Probability
Target price
$40.00
-42.2% vs current
AI sentiment snapshot
Latest data as of 2026-02-27
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+30.8
Score
AI commentary
Market commentary and price targets skew positive versus the anchor, reflecting analyst optimism around upcoming readouts and commercial potential [#SERP-1]. Short-term sentiment is mixed: some outlets show elevated price targets while others highlight downside scenarios tied to binary trial risk [#SERP-2][#SERP-3]. Overall tone is cautiously constructive but event-driven.
RankAlpha Sentiment AI - 2026-02-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-28catalystNear-term quarterly earnings & corporate updateHigh impact
Q1/2026 results and corporate update may include clinical datapoints and guidance that drive a rapid re-rate; market consensus and commentary referenced in analyst summaries [#SERP-3].
2026-09-30eventLate-stage pivotal readout (assumed window end)High impact
Potential pivotal readout for lead asset in H2 2026; no exact public date disclosed so conservatively using window end assumption — outcome would be binary and materially move valuation [#SERP-2].
2027-02-27catalystCommercial uptake and broader pipeline de-riskingHigh impact
Over a full year, successful regulatory steps and early commercial traction could re-rate the company toward peers; long-horizon adoption and multiple program readouts drive this scenario [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-27 • Updated nightlySource: Internal modelMethodology